Access to Focal Spasticity Care: A Cross Canada Survey of Physiatrists

Can J Neurol Sci. 2020 Nov;47(6):834-838. doi: 10.1017/cjn.2020.108. Epub 2020 Jun 4.

Abstract

Successful management of focal spasticity requires access to botulinum toxin type A (BoNT-A) injections, physiotherapy, occupational therapy, and orthoses/bracing. To assess the quality of focal spasticity care across Canada, we sent a survey consisting of 22 questions to physiatrists involved in the management of outpatient spasticity. Thirty-four physiatrists from all 10 provinces responded to the survey. Wait time for BoNT-A treatment averaged 12.7 weeks from time of referral across Canada. More than 75% of patients faced barriers to obtaining physical therapy and orthoses. Access to best quality care for spasticity patients across Canada varies widely.

Keywords: Neuromuscular disorders; Spasticity.

MeSH terms

  • Botulinum Toxins, Type A* / therapeutic use
  • Humans
  • Injections, Intramuscular
  • Muscle Spasticity / drug therapy
  • Neuromuscular Agents* / therapeutic use
  • Occupational Therapy*
  • Physiatrists*
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A